Abstract:Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory domain (eg, CD28 or 4-1BB [TNFRSF9, also known as CD137]). The B-cell maturation antigen (BCMA; TNFRSF17) is an attractive target for CAR T-cell therapy because it is only expressed by normal and malignant plasma cells and by a subset of mature B cells. Several trials of anti-BCMA CAR T cells have shown high-quality responses, including minimal residual disease-negativity in patients with multiple myeloma who were heavily pretreated. Phase 3 trials are currently evaluating CAR T-cell therapy versus standard-of-care regimens in patients in earlier stages of the disease. Trials are also ongoing in newly diagnosed patients with high-risk cytogenetic profiles or with residual disease after transplantation. CAR T cells targeting other multiple myeloma antigens, such as CD19, CD38, CD138 (SYND1), and SLAMF7, are also being explored. Toxicities associated with CAR T cells include cytokine-release syndrome, different types of cytopenia, infections, and neurotoxicity. Although some subsets of patients have sustained responses for more than 1 year, most patients eventually relapse, which might be related to the loss of CAR T cells, loss of antigen expression on the tumour cell surface, or to an immunosuppressive microenvironment that impairs the activity of T cells. Efforts to improve the effectiveness of CAR T-cell therapy include optimising CAR design and adapting the manufacturing process to generate cell products enriched for specific subsets of T cells (eg, early memory cells). Other strategies explored in trials include dual-antigen targeting to prevent antigen escape and rational combination therapy to enhance persistence. Several approaches are also being developed to improve the safety of CAR T-cell therapy, such as the incorporation of a suicide gene safety system.

The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma

BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

BCMA CAR-T cells in multiple myeloma–ready for take-off?

Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma

Update on the current and future use of CAR‐T to treat multiple myeloma

Current Advances in Chimeric Antigen Receptor T-cell Therapy for Refractory/relapsed Multiple Myeloma.

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Chimeric Antigen Receptor T Cells For The Treatment Of Multiple Myeloma

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

CAR T-cell therapy to treat multiple myeloma: current state and future directions

CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey

CAR T-cell therapy for multiple myeloma: state of the art and prospects

Development of CAR-T cell therapies for multiple myeloma

FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

Adoptive cell therapy in multiple Myeloma

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

CAR T therapies in multiple myeloma: unleashing the future